Peer-reviewed veterinary case report
Desmopressin given during surgery for advanced dog mammary cancer
By Hermo, Guillermo A et al.·Published in Journal of the American Animal Hospital Association·2011·Department of Science and Technology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of adjuvant perioperative desmopressin in locally advanced canine mammary carcinoma and its relation to histologic grade.
- Species:
- dog
Plain-English summary
A group of 28 female dogs with advanced mammary cancer (stage III or IV) underwent surgery to remove the affected glands. Half of the dogs received a medication called desmopressin during surgery, while the other half received a placebo. The dogs that received desmopressin had significantly longer periods without disease and overall survival compared to those that did not, especially if their tumors were more aggressive (grade 2 or 3). This suggests that desmopressin could be a helpful addition to treatment for dogs with serious mammary tumors.
People also search for: dog mammary cancer treatment · desmopressin for dogs · advanced dog cancer survival rates
Abstract
Desmopressin (DDAVP) is a vasopressin peptide analog with hemostatic properties that has been successfully used during surgery in patients with bleeding disorders. Recently published experimental and clinical data indicate that perioperative administration of DDAVP can minimize spread and survival of residual mammary cancer cells. The central aim of this study was to explore the effect of perioperative DDAVP and its relation to histologic grade in bitches with locally advanced mammary carcinoma. Of the 32 dogs initially recruited, 28 intact bitches with mammary carcinoma tumors stage III or IV were ultimately included. These dogs were randomized to receive DDAVP at intravenous doses of 1 μg/kg (n=18) or saline solution as placebo (n=10). En bloc mastectomy of the affected gland(s) was performed. Tumor malignancy was graded by the method of Elston and Ellis into well-differentiated (grade 1), moderately differentiated (grade 2), or poorly differentiated (grade 3). DDAVP therapy significantly prolonged the disease-free survival (P<0.001) and overall survival (P<0.01) in bitches with grade 2 or 3 carcinomas compared with bitches in the control group. No significant difference in disease-free period or overall survival was found between treatment groups in bitches with grade 1 tumors. The present data suggest that DDAVP may be an excellent candidate as a surgical adjuvant in the management of aggressive cancers in small animals. More research in this field is warranted.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21164169/